Oculis eye drops meet endpoints in Phase 3 trial

09 August 2023 10:13

Zurich CCGreater ZurichSwiss AMCHAM SoCal

Supporting partner

Zug/Boston - Oculis has proven in a Phase 3 trial that just one daily application of its eye drops can significantly reduce inflammation and pain following ocular surgery. The topical formulation previously recorded positive results in the treatment of Diabetic Macular Edema.

In a clinical trial launched in March 2023, Oculis has shown that the first eye drops for the front and back of the eye have the potential to effectively treat a further indication. According to a press release, the topical candidate OCS-01 met both primary endpoints in the OPTIMIZE Phase 3 trial launched in March 2023. With a once-daily dose of drops, there was an absence of pain and inflammation 4 days and 15 days after ocular surgery respectively.

According to the Zug-based company, if OCS-01 is approved it “has the potential to become a new standard of care as the first once-daily, topical, preservative-free corticosteroid for treating inflammation and pain following ocular surgery.” “This is significant for patients who have undergone cataract surgery, as they currently need to self-administer multiple daily doses of eye drops to alleviate inflammation and pain,” says Dr Eric Donnenfeld, Co-chair of Oculis’s Scientific Advisory Board.

Since the product also reaches the back of the eye, it could have potential for treating other conditions such as retinal edema. The company says the Phase 3 DIAMOND trial, an EU-funded Horizon 2020 research initiative, recorded statistically significant results for the treatment of Diabetic Macular Edema, as Oculis reported in May this year. The results also follow the launch of the LEOPARD trial, which is investigating the potential of OCS-01 for the treatment of Cystoid Macular Edema, one of the most common causes of vision loss after cataract surgery. ce/mm

Supporting partner

Swiss Pavilion Digital